Lale Tokgözoğlu: Significant CV Benefit of Lowering LDL to 44 mg/dL in Diabetes
Lale Tokgözoğlu, Professor of Cardiology at Hacettepe University, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Our analysis from the Vesalius trial showed significant benefit of lowering LDL to a median of 44 mg/dL in diabetics presented at ACC26.”
Title: Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Results From the VESALIUS-CV Trial
Authors: Nicholas A. Marston, Erin A. Bohula, Ajay K. Bhatia, Gaetano M. De Ferrari, Lawrence A. Leiter, Jose C. Nicolau, Jeong-Gun Park, Sabina A. Murphy, Emileigh Walsh, Lyrica Liu, Subodh Verma, Naveed Sattar, Stephen J. Nicholls, Jose Lopez-Sendon, Ioanna Gouni-Berthold, Lale Tokgozoglu, Ron Blankstein, Marcoli Cyrille, Gabriel Paiva da Silva Lima, Robert P. Giugliano, Marc S. Sabatine
Read the Full Article on Jama
More posts featuring Lale Tokgözoğlu on Hemostasis Today
-
Oct 3, 2026, 17:26Karel Kostev։ When First Anticoagulant Prescriptions Are Not Dispensed
-
Oct 3, 2026, 17:11Nabila Hasan: Thalassemia Awareness And Prevention
-
Oct 3, 2026, 17:03Pasinee Sangsiwarit: Neutrophil Dysfunction In β-Thalassemia
-
Oct 3, 2026, 16:18Mira Kassouf: Reactivating An Embryonic Gene To Treat α-Thalassemia
-
Oct 3, 2026, 15:49Behnood Bikdeli: COATED_AIR Trial Design Published as Enrollment Reaches 3,000 Patients
-
Oct 3, 2026, 15:25Vanrose Panashe Nyamangodo: A Multi-Task Deep Learning Model For Malaria And Anemia
-
Oct 3, 2026, 14:52Benny Sorensen: Glanzmann’s Thrombasthenia Finally Assigned Dedicated ICD-10 Code
-
Oct 3, 2026, 14:52The Real-World Burden Of DVT In Traumatic Fractures – ISTH
-
Oct 3, 2026, 14:41How Much Do We Really Know About The Global Burden Of Venous Thromboembolism? – World Thrombosis Day